Summit Therapeutics (SMMT) Tops Q1 EPS by 4c

Summit Therapeutics (NASDAQ: SMMT) reported Q1 EPS of (GBP0.24), GBP0.04 better than the analyst estimate of (GBP0.28).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NewAmsterdam Pharma (NAMS) call put ratio 1 call to 4.8 puts with a focus on 2K contracts of January 25 puts
• Lockheed, RTX, Boeing, L3Harris expected to meet with Trump - WSJ